Previous Close | 4.9700 |
Open | 4.8600 |
Bid | 4.5800 x 400 |
Ask | 4.7300 x 100 |
Day's Range | 4.6100 - 4.9243 |
52 Week Range | 2.8500 - 15.9000 |
Volume | |
Avg. Volume | 131,057 |
Market Cap | 56.266M |
Beta (5Y Monthly) | -0.11 |
PE Ratio (TTM) | 1.06 |
EPS (TTM) | 4.3500 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 60.00 |
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates.
Prenetics Global Limited (NASDAQ:PRE), a leading genomics-driven health sciences company, announces the signing of a Memorandum of Understanding (MOU), that paves the way for a strategic investment in Metavisionaries and a pioneering five-year research agreement with them and their partners Space Application Services through their Metaspace Venture. The parties will also establish a Space Innovation Lab within the UAE Space Agency. The inaugural Prenetics research cube is scheduled to on-board t
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial results for the third quarter ended September 30, 2023, along with recent business updates.